Events Partner Content 1st Molecular Glue Drug Development Summit Advance Molecular Glue Degraders into the Clinic
Events Partner Content 5th Annual Targeted Protein Degradation Summit Deliver Next Generation Degraders to Patients Faster
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
